Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Maintenance in Advanced Non-Squamous NSCLC
NCT00606021Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Pemetrexed + BSC with Best Supportive Care (2 arms). Primary endpoint: Progression Free Survival During Maintenance Phase up to 30.9 months. Started Jan 2008; status: completed.
02
Drugs
pemetrexed
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00606021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606021.